AtriCure (ATRC) investor relations material

Growth outlook and guidance for 2026

• Organic growth expected at 12%-14% for 2026, slightly higher than 2025 guidance, driven by strong product launches and expanding adoption in core areas.

• Pain management franchise, with recent product launches, is projected to outpace other segments, especially in the underpenetrated thoracic market.

• New device launch for pain management in amputation procedures offers additional upside as the market matures.

• Open heart surgery segment benefits from steady adoption of the EnCompass clamp and new AtriClip products, with growth in line with overall company guidance.

• Standalone Afib treatment (hybrid business) remains a headwind but is expected to decline less in 2026 compared to 2025.

Product innovation and adoption trends

• EnCompass clamp reduced procedure time from 30-45 minutes to 8-10 minutes, driving increased adoption, especially among CABG surgeons, with U.S. penetration rising to about 20% by end of 2025.

• Pain management devices like cryoSPHERE+ and cryoSPHERE MAX have accelerated adoption by significantly reducing procedure times, with minimal barriers to adoption despite reimbursement challenges.

• New cryoXT device targets post-amputation pain, addressing a growing market of 180,000 annual U.S. amputations, with strong initial feedback and a dedicated device design.

• AtriClip FLEX-Mini, launched in 2024, exceeded expectations with volume-driven growth and ASP uplift, driven by demand for smaller devices.

• AtriClip PRO-Mini enables minimally invasive procedures, but growth is limited by underlying procedure volume despite ASP improvements.

Competitive landscape and market dynamics

• Entry of new competitors in appendage management is seen as validation of market opportunity, with innovation and clinical science as key differentiators.

• Competition is expected to raise awareness and expand the market, with three major cardiac companies now active in appendage management.

• In pain management, cryoanalgesia is not new, but significant capital investment and differentiated technology are barriers for new entrants.